Evidence map›Paper›PMID 23007402›Full record

ArticleThe Journal of biological chemistry2012

Epidermal growth factor (EGF) regulates α5β1 integrin activation state in human cancer cell lines through the p90RSK-dependent phosphorylation of filamin A.

Daniel Vial, Paula J McKeown-Longo

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Regioselective Synthesis of aOrganic letters · 2020
    Article
  10. Review
  11. The Roles of Integrin α5β1 in Human Cancer.OncoTargets and therapy · 2020
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Integrin bondage: filamin takes control.Nature structural & molecular biology · 2015
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Daniel VialCenter for Cell Biology and Cancer Research, Albany Medical College, Albany, NY 12208, USA.
Paula J McKeown-Longo
Albany Medical Center Hospital · US

Funding

VITRONECTIN--STRUCTURE/FUNCTIONR01CA058626 · NCI · ALBANY MEDICAL COLLEGE · PI MC KEOWN-LONGO, PAULA J · 1993 to 2012
$3.3M
NCI NIH HHS R01 CA058626NCI NIH HHS R01 CA58626
6 · The paper itself

Abstract

backgroundRegulation of integrin activation has important implications for tumor cell invasion and metastasis.

resultsEGF activates ERK/p90RSK and Rho/Rho kinase signaling in A431 and DiFi colon cancer cells, leading to phosphorylation of filamin A (FLNa) and inactivation of the α5β1 integrin receptor.

conclusionEGF promotes α5β1 inactivation through the p90RSK-dependent phosphorylation of FLNa. SIGNIFICANCE: We have identified a novel EGF-dependent mechanism controlling the α5β1 integrin activation state. Cell adhesion, motility, and invasion are regulated by the ligand-binding activity of integrin receptors, transmembrane proteins that bind to the extracellular matrix. Integrins whose conformation allows for ligand binding and appropriate functional activity are said to be in an active state. Integrin activation and subsequent ligand binding are dynamically regulated by the association of cytoplasmic proteins with integrin intracellular domains. In this study, we evaluated the role of EGF in the regulation of the activation state of the α5β1 integrin receptor for fibronectin. The addition of EGF to either A431 squamous carcinoma cells or DiFi colon cancer cells resulted in loss of α5β1-dependent adhesion to fibronectin but no loss of integrin from the cell surface. EGF activated the EGF receptor/ERK/p90RSK and Rho/Rho kinase signaling pathways. Blocking either pathway inhibited EGF-mediated loss of adhesion, suggesting that they work in parallel to regulate integrin function. EGF treatment also resulted in phosphorylation of filamin A (FLNa), which binds and inactivates β1 integrins. EGF-mediated FLNa phosphorylation was completely blocked by an inhibitor of p90RSK and partially attenuated by an inhibitor of Rho kinase, suggesting that both pathways converge on FLNa to regulate integrin function. A431 clonal cell lines expressing non-phosphorylated dominant-negative FLNa were resistant to the inhibitory effects of EGF on integrin function, whereas clonal cell lines overexpressing wild-type FLNa were more sensitive to the inhibitory effect of EGF. These data suggest that EGF-dependent inactivation of α5β1 integrin is regulated through FLNa phosphorylation and cellular contractility.

Indexed as

Amino Acid MotifsCell Line, TumorContractile ProteinsEpidermal Growth FactorFilaminsHumansIntegrin alpha5beta1Microfilament ProteinsPhosphorylationRibosomal Protein S6 Kinases, 90-kDaContractile ProteinsEpidermal Growth FactorFilaminsIntegrin alpha5beta1Microfilament ProteinsRibosomal Protein S6 Kinases, 90-kDa

Identifiers

PMID23007402
PMCPMC3504752
OpenAlexW2036900657

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.